Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment
- 1 March 1978
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 27 (5) , 801-802
- https://doi.org/10.1016/0006-2952(78)90525-7
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASEThe Lancet, 1977
- Substrate-selective inhibition of monoamine oxidase by some cyclopropylamino substituted oxadiazolesBiochemical Pharmacology, 1976
- The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formationEuropean Journal of Pharmacology, 1975
- The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenilJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1975
- Rates of recovery of irreversibly inhibited monoamine oxidases: A measure of enzyme protein turnoverNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1972
- Evidence for a specific monoamine oxidase associated with sympathetic nervesNeuropharmacology, 1971
- Further studies on the inhibition of monoamine oxidase by M & B 9302 (clorgyline)—I: Substrate specificity in various mammalian speciesBiochemical Pharmacology, 1969
- Some observations upon a new inhibitor of monoamine oxidase in brain tissueBiochemical Pharmacology, 1968
- A sensitive and specific assay for the estimation of monoamine oxidaseBiochemical Pharmacology, 1963
- Studies with reversible inhibitors of monoamine oxidase: Harmaline and related compoundsBiochemical Pharmacology, 1958